MA-WASABI-TECHNOLOGIES
9.4.2024 14:01:32 CEST | Business Wire | Press release
Wasabi Technologies, the hot cloud storage company, today introduced Wasabi AiR™, the industry's first AI-enabled intelligent media storage. Wasabi AiR combines Wasabi’s high-performance, low-cost object storage with advanced AI metadata auto-tagging and multilingual searchable speech-to-text transcription. Video files uploaded to Wasabi AiR are immediately analyzed and a second-by-second metadata index is created, enabling users to quickly find what they are looking for. Wasabi AiR greatly reduces the cost of metadata creation: with Wasabi AiR, customers pay only for the storage. There is no additional charge for use of the AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409707430/en/
In January, Wasabi announced its acquisition of Curio AI, a state-of-the-art AI platform designed specifically to analyze and index large video archives. Now users simply upload their video files to Wasabi AiR storage and the AI automatically goes to work generating a rich second-by-second metadata index. Wasabi AiR uses facial recognition, searchable speech-to-text, multi-lingual translation, speaker recognition, optical text recognition, logo identification, and sounds recognition with unparalleled accuracy. Video archives currently stored on tape can be uploaded to Wasabi AiR storage and formerly “dead” content can become a new source of revenue and user engagement. Wasabi AiR is purpose-built for use cases including:
- Post-production: Quickly find and assemble video for news packages, highlight reels, social media content and more in real time to enable production teams to focus on creativity without being bogged down searching for content
- Sponsorship and marketing ROI: Find logos for sponsorship attribution with ease for ROI analysis
- Geo-diversity: Tailor content to specifically meet the requirements of geo-diverse audiences
“Wasabi AiR introduces a solution to a persistent 25-year-old challenge, combining AI-driven search capabilities with high-performance cloud storage,” said Dave McCarthy, research vice president at IDC. “This marks a transformative shift in media management, offering efficiency and accessibility for businesses dealing with massive unstructured data. Wasabi AiR represents a significant advancement in tackling the longstanding issue of managing extensive data archives, within a substantial market for intelligent media storage solutions."
“Why move to the cloud if you still can’t find anything?” said David Friend, co-founder and chief executive officer, Wasabi Technologies. “Object storage without metadata is like a library without a catalog. Wasabi AiR works right out of the box and it’s as simple to use as popular search engines. For example, if it finds a face that it doesn’t recognize, it asks ‘Who is this?’ Using a simple UI, the user can train their own models. You can have tens of thousands of hours of video, and Wasabi AiR will take you right to the moment you are looking for. And you can search as much as you want – we only charge for the storage.”
Transformative Price Predictability and Performance Accuracy
Media organizations are operating under tighter deadlines and narrower profit margins and are looking for ways to speed production workflows while controlling costs. Wasabi AiR’s inexpensive, capacity-based pricing allows users the freedom to work with their content without being penalized with unpredictable fees for AI analysis, egress, or API requests, at a price up to 80% less than competitors. Both source files and metadata are owned exclusively by each customer – Wasabi never uses our customer’s proprietary data to train models that others can use. Files and metadata are secure and protected from ransomware, disasters or accidental deletions by Wasabi’s immutable storage and unique multi-user authentication.
“Wasabi AiR significantly reduces our manual efforts due to its seamless use of AI recognition technology to identify, organize and categorize files,” said Drew Crisp, Senior Vice-President of Digital at Liverpool Football Club. “At the club we handle extensive media content, and so this enhanced efficiency could really help us to locate specific content quickly and accurately within our archive, and create new content streams quickly, empowering our creativity and innovation. Wasabi AiR transcends mere storage; it will become another key to unlocking the full potential of our content.”
Learn more:
- Wasabi AiR is available this quarter. Please visit here or stop by the Wasabi booth SL8117 at NAB April 14-17 for a demo or book a meeting to learn more about how Wasabi cloud storage can enhance media workflows
- See the savings Wasabi AiR enables with the cost calculator based on hours of video, bit rates and monthly amount of downloaded content
About Wasabi Technologies
Recognized as one of the technology industry’s fasting growing companies, Wasabi is on a mission to store the world's data by making cloud storage affordable, predictable and secure. With Wasabi, visionary companies gain the freedom to use their data whenever they like without being hit with unpredictable fees or vendor lock-in. Instead, they’re free to build best-of-breed solutions with the industry’s fastest-growing ecosystem of independent cloud application partners. Customers and partners all over the world trust Wasabi to help them put their data to work so they can unlock their full potential. Visit wasabi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409707430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
